Zygote Ventures

Zygote focuses on seed and pre-seed stages, writing first checks into companies at the earliest point of formation. The firm's name underscores the strategy — it aims to back founders when the venture is still a zygote, before product-market fit or institutional traction. Follow-on participation through Series A is part of the stated approach.

The firm's Berkeley headquarters suggests a sourcing model anchored in the University of California, Berkeley, and Lawrence Berkeley National Laboratory ecosystems. Zygote likely focuses on academic spinouts and scientist-founders, drawing from deep-tech research in AI, life sciences, and engineering. This proximity-driven model differentiates Zygote from accelerator-backed or inbound-marketing-dependent seed funds.

No. Zygote Ventures does not publicly disclose its assets under management, fund sizes, or deployment figures. The firm maintains a low public profile with no reported fund closes in the trade press. Any AUM figure would require direct disclosure from the firm.

Zygote Ventures does not publicly list its investment team, principals, or limited partners. The firm's partnership structure and decision-making process remain undisclosed. No individual investment professionals have been named in public records or trade publications.

While Zygote likely shares a venture studio's appetite for company formation, the firm operates as a discretionary venture fund rather than a studio that co-locates and actively incubates founders. The structural difference lies in independence: Zygote backs founders who are building within their own research or commercial environments, not within a centralized studio platform.